Compliance Rate
Compliance Rate
0%
Compliant submissions
0
Incompliant submissions
0
Total trials
0
My Organizations' Clinical Trials
Showing 2 of 2 entries
View as:
Phase: N/A
Priority: Normal
Start: 09/10/17
End: 08/08/26
Due: 08/08/27
Phase: N/A
Priority: Normal
Start: 10/13/23
End: 10/31/26
Due: 10/31/27
| Title | NCT ID | Organization | User | Status | Start Date | End Date | Reporting Due Date | Last Checked | User Role | Org Created |
|---|---|---|---|---|---|---|---|---|---|---|
| Pembrolizumab in Combination With Olaparib in Advanced BRCA-mutated or HDR-defect Breast Cancer | NCT03025035 | Yuan Yuan | user2@example.com | None | 2017-09-10 | 2026-08-08 | 2027-08-08 | - | - | 2025-07-14 |
| Ivermectin and Balstilimab for the Treatment of Metastatic Triple Negative Breast Cancer | NCT05318469 | Yuan Yuan | user2@example.com | None | 2023-10-13 | 2026-10-31 | 2027-10-31 | - | - | 2025-07-14 |